EO9 (Apaziquone): From the clinic to the laboratory and back again

British Journal of Pharmacology

Volumn 168, Issue 1, 2013, Pages 11-18

  Phillips, Roger M ^a   Hendriks, Hans R ^b   Peters, Godefridus J ^c  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b Hendriks Pharmaceutical Consulting   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apaziquone; bioreductive prodrugs; bladder cancer; EO9; Eoquin; hypoxia; NQO1

Indexed keywords

APAZIQUONE;

ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; BREAST CANCER; COLORECTAL CANCER; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERABILITY; DYSURIA; HEMATURIA; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; REVIEW; STOMACH CANCER; TRANSITIONAL CELL CARCINOMA;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; AZIRIDINES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, TRANSITIONAL CELL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEQUINONES; LUNG NEOPLASMS; TREATMENT FAILURE; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84872835507     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01996.x     Document Type: Review

References (76)

1. Aamdal S, Lund B, Koier I, Houten M, Wanders J, Verweij J, (2000). Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG). Cancer Chemother Pharmacol 45: 85-88.
2. Adams GE, Stratford IJ, Edwards HS, Bremner JC, Cole S, (1992). Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9. Int J Radiat Oncol Biol Phys 22: 717-720.
3. Bailey SM, Lewis AD, Knox RJ, Patterson LH, Fisher GR, Workman P, (1998). Reduction of the indoloquinone anticancer drug EO9 by purified DT-diaphorase: a detailed kinetic study and analysis of metabolites. Biochem Pharmacol 56: 613-621.
4. Bailey SM, Lewis AD, Patterson LH, Fisher GR, Knox RJ, Workman P, (2001). Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. Biochem Pharmacol 62: 461-468.
5. Basu S, Brown JE, Flannigan GM, Gill JH, Loadman PM, Martin SW, et al,. (2004). Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. Int J Cancer 109: 703-709.
6. Bibby MC, Cronin BP, Phillips RM, (1993a). Evaluation of the cytotoxicity of the indolequinone EO9 in a human colon adenocarcinoma model. Int J Oncol 3: 661-666.
7. Bibby MC, Sleigh NR, Loadman PM, Double JA, (1993b). Potentiation of EO9 anti-tumour activity by hydralazine. Eur J Cancer 29A: 1033-1035.
8. Burd R, Lavorgna SN, Lenaz L, Chawla S, Reddy G, Wachsberger R, et al,. (2005). Tumour radiosensitization by apaziquone (EO9, EOquin). Proc Am Assoc Cancer Res 46, abstract number 1454.
9. Butler J, Spanswick VJ, Cummings J, (1996). The autoxidation of the reduced forms of EO9. Free Radic Res 25: 141-148.
10. Cadenas E, (1995). Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem Pharmacol 49: 127-140.
11. Ceelen WP, Flessner MF, (2010). Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 7: 108-115.
12. Choudry GA, Hamilton Stewart PA, Double JA, Krul MRL, Naylor B, Flannigan GM, et al,. (2001). A novel styrategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC1.6.99.2) mediated therapy of bladder cancer based on the pharmacologocal properties of EO9. Br J Cancer 85: 1137-1146.
13. Collard J, Matthew AM, Double JA, Bibby MC, (1995). EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer 71: 1199-1203.
14. Connors TA, (1996). Bioreductive agents, hypoxic cells and therapy. Eur J Cancer 32A: 1833-1834.
15. Cowan DS, Hicks KO, Wilson WR, (1996). Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br J Cancer Suppl 27: S28-S31.
16. Cummings J, Spanswick VJ, Gardiner J, Ritchie A, Smyth JF, (1998). Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9. Biochem Pharmacol 55: 253-260.
17. Denny WA, (2004). Prospects for hypoxia-activated anticancer drugs. Curr Med Chem Anticancer Agents 4: 395-399.
18. Dirix LY, Tonnesen F, Cassidy J, Epelbaum R, ten Bokkel Huinink WW, Pavlidis N, et al,. (1996). EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer 32A: 2019-22.
19. Ernster L, (1987). DT Diaphorase: a historical review. Chem Scr 27A: 1-13.
20. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD, (1996). Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88: 259-269.
21. Gofrit ON, Zorn KC, Shikanov S, Steinberg GD, (2010). Marker lesion experiments in bladder cancer-what have we learned? J Urol 183: 1678-1684.
22. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, et al,. (2007). Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178: 2314-2330.
23. Hargreaves RH, Hartley JA, Butler J, (2000). Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones. Front Biosci 5: E172-E180.
24. Hay MP, Hicks KO, Pruijn FB, Pchalek K, Siim BG, Wilson WR, et al,. (2007a). Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. J Med Chem 50: 6392-6404.
25. Hay MP, Pchalek K, Pruijn FB, Hicks KO, Siim BG, Anderson RF, et al,. (2007b). Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity. J Med Chem 50: 6654-6664.
26. Hay MP, Hicks KO, Pchalek K, Lee HH, Blaser A, Pruijn FB, et al,. (2008). Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins. J Med Chem 51: 6853-6865.
27. van der Heijden AG, Moonen PM, Cornel EB, Vergunst H, de Reijke TM, van Boven E, et al,. (2006). Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176: 1349-1353; discussion 1353.
28. Hendricksen K, Gleason D, Young JM, Saltzstein D, Gershman A, Lerner S, et al,. (2008). Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol 180: 116-120.
29. Hendricksen K, van der Heijden AG, Cornel EB, Vergunst H, de Reijke TM, van Boven E, et al,. (2009). Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol 27: 337-342.
30. Hendriks HR, Pizao PE, Berger DP, Kooistra KL, Bibby MC, Boven E, et al,. (1993). EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A: 897-906.
31. Jain A, Phillips RM, Scally AJ, Lenaz G, Beer M, Puri R, (2009). Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology 73: 1083-1086.
32. Loadman PM, Bibby MC, Phillips RM, (2002). Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol 137: 701-709.
33. Lu Z, Wang J, Wientjes MG, Au JL, (2010). Intraperitoneal therapy for peritoneal cancer. Future Oncol 6: 1625-1641.
34. McKeown SR, Cowen RL, Williams KJ, (2007). Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol) 19: 427-442.
35. McLeod HL, Graham MA, Aamdal S, Setanoians A, Groot Y, Lund B, (1996). Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group. Eur J Cancer 32A: 1518-1522.
36. Maliepaard M, Wolfs A, Groot SE, de Mol NJ, Janssen LH, (1995). Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase. Br J Cancer 71: 836-839.
37. Masters JR, McDermott BJ, Jenkins WE, Fenwick E, Shah PJ, Mundy AR, et al,. (1990). ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80. Cancer Chemother Pharmacol 25: 267-273.
38. Masters JR, McDermott BJ, Harland S, Bibby MC, Loadman PM, (1996). ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour. Cancer Chemother Pharmacol 38: 59-64.
39. Milbank JB, Stevenson RJ, Ware DC, Chang JY, Tercel M, Ahn GO, et al,. (2009). Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihy dro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins. J Med Chem 52: 6822-6834.
40. Minchinton AI, Tannock IF, (2006). Drug penetration in solid tumours. Nat Rev Cancer 6: 583-592.
41. Oostveen EA, Speckamp WN, (1987). Mitomycin analogues 1. Indolequinones as potent bisalkylating agents. Tetrahedron 43: 255-262.
42. Pavlidis N, Hanauske AR, Gamucci T, Smyth J, Lehnert M, te Velde A, et al,. (1996). A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 7: 529-531.
43. Phillips RM, (1996). Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase. Biochem Pharmacol 52: 1711-1718.
44. Phillips RM, Clayton MR, (1997). Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours. Br J Cancer 75: 196-201.
45. Phillips RM, Hulbert PB, Bibby MC, Sleigh NR, Double JA, (1992). In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer 65: 359-364.
46. Phillips RM, Loadman PM, Cronin BP, (1998). Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer 77: 2112-2119.
47. Phillips RM, Naylor MA, Jaffar M, Doughty SW, Everett SA, Breen AG, et al,. (1999). Bioreductive activation of a series of indolequinones by human DT-diaphorase: structur-activity relationships. J Med Chem 42: 4071-4080.
48. Phillips RM, Jaffar M, Maitland DJ, Loadman PM, Shnyder SD, Steans G, et al,. (2004). Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. Biochem Pharmacol 68: 2107-2116.
49. Pizao PE, Peters GJ, Van Ark-Otte J, Smets LA, Smitskamp-Wilms E, Winograd B, et al,. (1993). Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. Eur J Cancer 29A: 1566-1573.
50. Plumb JA, Workman P, (1994). Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 56: 134-139.
51. Plumb JA, Gerritsen M, Milroy R, Thomson P, Workman P, (1994a). Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys 29: 295-299.
52. Plumb JA, Gerritsen M, Workman P, (1994b). DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer 70: 1136-1143.
53. Puri R, Palit V, Loadman PM, Flannigan M, Shah T, Choudry GA, et al,. (2006). Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer. J Urol 176: 1344-1348.
54. Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH, (2011). Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 11: 167-177.
55. Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE, (1992). The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem Pharmacol 44: 409-412.
56. Robertson N, Haigh A, Adams GE, Stratford IJ, (1994). Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 30A: 1013-1019.
57. Roed H, Aabo K, Vindelov L, Spang-Thomsen M, Christensen IB, Hansen HH, (1989). In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung. Eur J Cancer Clin Oncol 25: 1197-1201.
58. Schellens JH, Planting AS, van Acker BA, Loos WJ, de Boer-Dennert M, van der Burg ME, et al,. (1994). Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst 86: 906-912.
59. van der Schoot SC, Nuijen B, Flesch FM, Gore A, Mirejovsky D, Lenaz L, et al,. (2007a). Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle. AAPS PharmSciTech 8: E61.
60. van der Schoot SC, Vainchtein LD, Beijnen JH, Gore A, Mirejovsky D, Lenaz L, et al,. (2007b). EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studies. Int J Pharm 329: 135-141.
61. van der Schoot SC, Vainchtein LD, Nuijen B, Gore A, Mirejovsky D, Lenaz L, et al,. (2008). Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrin. Pharmazie 63: 796-805.
62. Segura-Aguilar J, Cremades A, Llombart-Bosch A, Monsalve E, Ernster L, Romero FJ, (1994). Activity and immunohistochemistry of DT-diaphorase in hamster and human kidney tumours. Carcinogenesis 15: 1631-1636.
63. Siegel D, Ross D, (2000). Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 29: 246-253.
64. Siegel D, Franklin WA, Ross D, (1998). Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 4: 2065-2070.
65. Smitskamp-Wilms E, Peters GJ, Pinedo HM, van Ark-Otte J, Giaccone G, (1994). Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem Pharmacol 47: 1325-1332.
66. Stratford IJ, Workman P, (1998). Bioreductive drugs into the next millennium. Anticancer Drug Des 13: 519-528.
67. Sylvester RJ, Oosterlinck W, van der Meijden AP, (2004). A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171: 2186-2190, quiz 2435.
68. Tercel M, Atwell GJ, Yang S, Stevenson RJ, Botting KJ, Boyd M, et al,. (2009). Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents. J Med Chem 52: 7258-7272.
69. Vaupel P, Mayer A, (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26: 225-239.
70. Vaupel P, Kelleher DK, Hockel M, (2001). Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28: 29-35.
71. Walton MI, Smith PJ, Workman P, (1991). The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun 3: 199-206.
72. Walton MI, Bibby MC, Double JA, Plumb JA, Workman P, (1992). DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer 28A: 1597-1600.
73. Workman P, (1994). Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 6: 461-475.
74. Workman P, Walton MI, (1990). Enzyme directed bioreductive drug development. In:, Adams GE, Breccia A, Fielden EM, Wardman P, (eds). Selective Activation of Drugs by Redox Processes. Plenum Press: New York, pp. 173-191.
75. Workman P, Binger M, Kooistra KL, (1992). Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. Int J Radiat Oncol Biol Phys 22: 713-716.
76. Zappa F, Ward T, Pedrinis E, Butler J, McGown A, (2003). NAD(P)H: quinone oxidoreductase 1 expression in kidney podocytes. J Histochem Cytochem 51: 297-302.